Inaspir (Salmeterol)

Salmeterol selectively stimulates β2‑adrenergic receptors on airway smooth‑muscle cells, activating adenylate cyclase and raising cyclic AMP levels. The increased cAMP causes relaxation of bronchial smooth muscle, resulting in sustained bronchodilation that can last up to 12 hours after a single inhalation.

The prescribed dose of Inaspir is determined by the treating physician based on the individual’s disease severity, age, and response to therapy. Dosing instructions are provided on the product label and must be followed exactly as directed by a qualified healthcare professional.

Safety data for salmeterol during pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made in consultation with a healthcare provider.

To request Inaspir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inaspir (salmeterol) is a long‑acting β2‑agonist, offering bronchodilation for up to 12 hours, whereas short‑acting β2‑agonists such as albuterol provide relief for 4–6 hours. Compared with other LABAs like formoterol, salmeterol has a slower onset but a similar duration, and it is typically used in combination with inhaled corticosteroids for optimal asthma control.

Inaspir should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the inhaler cap closed when not in use and avoid exposing the device to extreme temperatures or humidity, which could affect dose accuracy.

Inaspir is delivered via a metered‑dose inhaler. The patient should inhale slowly and deeply, actuate the inhaler at the start of inhalation, and hold the breath for several seconds before exhaling. The device should be primed according to the manufacturer’s instructions before the first use and after a period of non‑use.

The most serious risks include paradoxical bronchospasm, which can worsen breathing, and cardiovascular events such as tachyarrhythmias or chest pain. Rarely, severe allergic reactions like anaphylaxis may occur. Patients should seek immediate medical attention if they experience sudden worsening of symptoms, chest discomfort, rapid heartbeat, or signs of an allergic reaction.

Inaspir is contraindicated in patients with known hypersensitivity to salmeterol or any component of the inhaler. It should also be avoided in individuals who have experienced a severe asthma attack requiring intubation or in those using non‑selective β‑blockers, as these conditions may increase the risk of adverse reactions. Consultation with a healthcare professional is essential before initiating therapy.